Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,541–1,550 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1541
- Medicine slug
- tolvaptan
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
56%
- Numeric value
- 56
- Unit
- %
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3febc0a1-9e5a-4ce0-843d-210f21d862c4 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The absolute bioavailability of tolvaptan following an oral dose of 30 mg is 56% (range 42% to 80%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f4c5679-8490-45ec-bd34-1a569e3af850 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The absolute bioavailability of tolvaptan following an oral dose of 30 mg is 56% (range 42 to 80%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b14ba2b-9f80-41d6-9613-f16d3cf37d25 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The absolute bioavailability of tolvaptan following an oral dose of 30 mg is 56% (range 42 to 80%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82ef58ef-ce46-434e-bf99-89fce51094f1 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The absolute bioavailability of tolvaptan following an oral dose of 30 mg is 56% (range 42 to 80%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9fd11d0-4269-12fb-95cf-b3c11d75e479 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The absolute bioavailability of tolvaptan following an oral dose of 30 mg is 56% (range 42 to 80%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92ce12f1-eae0-4c83-9a4e-a5181e08fa92 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The absolute bioavailability of tolvaptan following an oral dose of 30 mg is 56% (range 42 to 80%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c075d517-f4c8-469a-9f51-416ef61c6a83 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The absolute bioavailability of tolvaptan following an oral dose of 30 mg is 56% (range 42 to 80%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5526617c-c7b9-4556-886d-729bbabbc566 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The absolute bioavailability of tolvaptan following an oral dose of 30 mg is 56% (range 42 to 80%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd71ee70-9435-4715-bee5-edbb5a8d7d7b (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The absolute bioavailability of tolvaptan following an oral dose of 30 mg is 56% (range 42 to 80%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ba38e23-ca66-4406-92af-bbb8fad00e16 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The absolute bioavailability of tolvaptan following an oral dose of 30 mg is 56% (range 42 to 80%).
Projected row 1542
- Medicine slug
- tolvaptan
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
180 h
- Numeric value
- 180
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3febc0a1-9e5a-4ce0-843d-210f21d862c4 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The oxobutyric acid metabolite shows a plasma half-life of ~180 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f4c5679-8490-45ec-bd34-1a569e3af850 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The oxobutyric acid metabolite shows a plasma half-life of ~180 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b14ba2b-9f80-41d6-9613-f16d3cf37d25 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The oxobutyric acid metabolite shows a plasma half-life of ~180 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82ef58ef-ce46-434e-bf99-89fce51094f1 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The oxobutyric acid metabolite shows a plasma half-life of ~180 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9fd11d0-4269-12fb-95cf-b3c11d75e479 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The oxobutyric acid metabolite shows a plasma half-life of ~180 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92ce12f1-eae0-4c83-9a4e-a5181e08fa92 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The oxobutyric acid metabolite shows a plasma half-life of ~180 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c075d517-f4c8-469a-9f51-416ef61c6a83 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The oxobutyric acid metabolite shows a plasma half-life of ~180 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5526617c-c7b9-4556-886d-729bbabbc566 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The oxobutyric acid metabolite shows a plasma half-life of ~180 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd71ee70-9435-4715-bee5-edbb5a8d7d7b (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The oxobutyric acid metabolite shows a plasma half-life of ~180 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ba38e23-ca66-4406-92af-bbb8fad00e16 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The oxobutyric acid metabolite shows a plasma half-life of ~180 h.
Projected row 1543
- Medicine slug
- tolvaptan
- Compared field
- proteinBinding
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 0.9
- Recorded readings
>98%
- Numeric value
- 98
- Unit
- %
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3febc0a1-9e5a-4ce0-843d-210f21d862c4 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
Distribution Tolvaptan binds to both albumin and α1-acid glycoprotein and the overall protein binding is >98%; binding is not affected by disease state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f4c5679-8490-45ec-bd34-1a569e3af850 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
Distribution Tolvaptan binds to both albumin and α1-acid glycoprotein and the overall protein binding is >98%; binding is not affected by disease state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b14ba2b-9f80-41d6-9613-f16d3cf37d25 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
Distribution Tolvaptan binds to both albumin and α1-acid glycoprotein and the overall protein binding is >98%; binding is not affected by disease state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9fd11d0-4269-12fb-95cf-b3c11d75e479 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
Distribution Tolvaptan binds to both albumin and α1-acid glycoprotein and the overall protein binding is >98%; binding is not affected by disease state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92ce12f1-eae0-4c83-9a4e-a5181e08fa92 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
Distribution Tolvaptan binds to both albumin and α1-acid glycoprotein and the overall protein binding is >98%; binding is not affected by disease state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c075d517-f4c8-469a-9f51-416ef61c6a83 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
Distribution Tolvaptan binds to both albumin and α1-acid glycoprotein and the overall protein binding is >98%; binding is not affected by disease state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5526617c-c7b9-4556-886d-729bbabbc566 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
Distribution Tolvaptan binds to both albumin and α1-acid glycoprotein and the overall protein binding is >98%; binding is not affected by disease state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd71ee70-9435-4715-bee5-edbb5a8d7d7b (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
Distribution Tolvaptan binds to both albumin and α1-acid glycoprotein and the overall protein binding is >98%; binding is not affected by disease state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ba38e23-ca66-4406-92af-bbb8fad00e16 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
Distribution Tolvaptan binds to both albumin and α1-acid glycoprotein and the overall protein binding is >98%; binding is not affected by disease state.
98%
- Numeric value
- 98
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82ef58ef-ce46-434e-bf99-89fce51094f1 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
Distribution: Tolvaptan binds to both albumin and α1-acid glycoprotein and the overall protein binding is greater than 98%; binding is not affected by disease state.
Projected row 1544
- Medicine slug
- tolvaptan
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
3 L/kg
- Numeric value
- 3
- Unit
- L/kg
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3febc0a1-9e5a-4ce0-843d-210f21d862c4 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The volume of distribution of tolvaptan is about 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f4c5679-8490-45ec-bd34-1a569e3af850 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The volume of distribution of tolvaptan is about 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b14ba2b-9f80-41d6-9613-f16d3cf37d25 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The volume of distribution of tolvaptan is about 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82ef58ef-ce46-434e-bf99-89fce51094f1 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The volume of distribution of tolvaptan is about 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9fd11d0-4269-12fb-95cf-b3c11d75e479 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The volume of distribution of tolvaptan is about 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92ce12f1-eae0-4c83-9a4e-a5181e08fa92 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The volume of distribution of tolvaptan is about 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c075d517-f4c8-469a-9f51-416ef61c6a83 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The volume of distribution of tolvaptan is about 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5526617c-c7b9-4556-886d-729bbabbc566 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The volume of distribution of tolvaptan is about 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd71ee70-9435-4715-bee5-edbb5a8d7d7b (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The volume of distribution of tolvaptan is about 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ba38e23-ca66-4406-92af-bbb8fad00e16 (opens source in a new tab)
Tolvaptan label
Version not recorded · Effective date not recorded
The volume of distribution of tolvaptan is about 3 L/kg.
Projected row 1545
- Medicine slug
- topiramate
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 155
- Source count
- 134
- Agreement rate
- 1
- Recorded readings
80%
- Numeric value
- 80
- Unit
- %
- Source records
- 134
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 134 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2917ba32-3355-4d64-966a-8518e6fafdbe (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bd03bb2-3b9b-4707-a9a4-5618ddc3832f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9cb3c29-098c-405f-a200-b436ac7fa1a2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f781ada8-f90d-b233-e053-6394a90a87ff (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:149d20de-f262-4567-aa97-d4d28a1653cb (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f461f84-bfad-44fa-a2bd-5ea1566444b5 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53c3f980-f05b-c671-e063-6294a90a77d5 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5461f33d-eaef-dce3-e063-6294a90aeff8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:163e9f2d-27be-6d3f-e063-6394a90a5884 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:562f3fec-489b-4662-e063-6294a90a4ea2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46a305cb-ab73-0bca-e063-6294a90a9b85 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cefbc5f4-ef5f-4732-ab96-a69a183f0b6b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e0834ee-920b-496f-954d-f9d81c3ba2d6 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c909a53-ae66-4b28-a741-b60bb25a69cf (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68b22d22-c2d3-4e90-b302-56f7cb731427 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb966bcb-3af7-4dbe-b540-58d473b891e5 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b6b0642-fb91-4641-9c51-d3be2021992b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf732c34-9078-496a-8093-f68594e76fcb (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61390be3-7553-4cb5-b5da-7571ed7d4b17 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffaacad8-4594-45a8-b292-02a84cd0c35b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a712d050-d5de-4685-a80a-548ab080fdb7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d6d236b-9808-4e18-b521-e7435d1fd5cc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc918c0d-2b1e-4fa0-b4d3-9dbc28718018 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30ca2fce-4e4c-439e-e063-6294a90af076 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:073d075d-d019-4834-b55d-9b9587914975 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21628112-0c47-11df-95b3-498d55d89593 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffd7be08-050e-dfcb-e053-6394a90ad286 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9221403c-467f-738e-e053-2995a90ac8fd (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca9ce6c1-5a60-467a-9ad5-acc7a9f8ca15 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:816566bf-b909-606f-e053-2a91aa0ab8c9 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:654f7c48-8c5d-4b97-88d6-397696f82b6a (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:521be3f1-3ee7-45c7-9f0c-17e08b6c8fca (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1af94c80-2b17-409a-98f6-ce00f942351d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5bc696e-040d-4d3e-b38c-9548a38fa936 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ee00e82-799d-445e-b658-a9712c49a28e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8abe45eb-cc75-4625-ae3d-5b2a038c4907 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92637f92-9d7c-c246-e053-2995a90a0347 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:872927eb-0b61-44bb-9892-3c700b6f2181 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e476c33-3590-4c6f-981d-915623cdacf0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f2aca4-b961-a746-e063-6294a90ae8ce (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be42ed09-350c-4e8a-aff4-6afb242dd599 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80481455-7ad7-4f44-8113-b8b61d8581a0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8706a35d-5c39-4daf-b83a-65f3d630e043 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e39d2549-b489-426d-b576-741537e112e7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1588c37-9da9-4ccb-b78a-64234938a115 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32b48ea0-a215-43b8-83b4-a5435a686d68 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35312f49-decf-428d-bf5f-4215b762ed3c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7539f52-06e9-4663-b401-92f5f83653cc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ce65b7f-9215-47a8-a784-f87a810bd7e4 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0cf388dc-d8f1-4478-bf5f-e64638ee5801 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b71c09c5-43dd-4d98-9ab6-0b0c99908cac (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67dcdd6e-48bc-418e-a887-805929d83ce0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d6752ce-7a56-4b04-ab15-cbd40aa5cc94 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7f2d1bc-9c65-4798-826f-6902b3ec81dc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cf7ce9e-afc2-f94e-e063-6394a90a35d0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f99b26b-79b9-4efb-aa2c-2868e1e126c8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55e71f43-1cd5-4efc-9641-fda0a09c30f0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3321dc5-0fb7-0d12-e053-2a95a90a9694 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f5b1b0b-fd8a-4c4e-a85a-519ca841a0db (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b847969-2124-4350-94b0-ef5ba707673b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57462baf-2f32-4bde-9627-2214c8af9370 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bffcd213-4f09-4a5b-8ccb-591a68be402b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:484c132f-3d3d-4218-b22f-82e9b56cc2f4 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8aaf403-0e15-4bbb-b88b-253d93439688 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c90d81a9-a87b-48b0-8cf1-172b82e30127 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d9513e0-2fb8-46c9-bbd6-b03efd31c3ef (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eca774cf-2e4e-7642-e053-2a95a90a847d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57ac12ed-27f0-4f5c-96ae-a7433714b429 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:584e16c5-5ffb-4bfc-ba80-4340afd25e8e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b353e7fb-b976-96d8-e053-2995a90a110a (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49701840-5a32-4ac1-8b07-5c61decacb95 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f16b14a2-297f-4adb-8d7a-5f43785faef7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:674c2c2e-014a-43a1-91a7-7214ffc4b1d7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fb00bd8-c49e-46ef-9d6b-1b602e1d11d8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8454fdf-7b34-49c0-b130-732e39b774b2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c0a6774-e234-47a5-866e-462cfd99744c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f327383-beb3-4d15-add6-5f1c749f2b3f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5cffe7a-fdee-487a-bafb-a2d43e76c23c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6918801-f22c-4ba4-a396-da484d4334ca (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:021005ab-6a00-40d8-9aee-20c91613b4d5 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12cd9be8-c5c2-4a16-9164-87963e22a88e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e846124d-e9e6-42c7-83f1-5df170d3f70b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:610d4df7-703f-4070-9adc-3e57ca05a2f1 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:444464fb-6a95-4e10-99a7-fdbc7dbb4c48 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9c4e279-0ef9-4e96-8741-dfe7556953d9 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ddb8451-a455-87ec-e053-2995a90a5e5e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c320999e-b940-44d8-bf31-2fb78835ac2d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca4ec248-285d-4066-8f89-5ed0c538c4c9 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:490f109f-30cb-0790-e054-00144ff88e88 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4087eb3c-96e9-4d0a-b80b-663e1c86d256 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f1e4475-6326-47a3-a317-b04b74b7c109 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae63e0e2-ceb1-4cc7-88fa-92cfa4516960 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0d88f34-865c-441b-80e2-e814c9a7d670 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4833f2e8-16b7-406f-937a-55bc978bf92c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be14624b-7eb9-4e7a-9274-1bb88270ecbe (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f66a529d-ba9d-4c8b-b58e-8fbcbcb8a11b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea0bcab1-cfe1-491c-875e-8c865449557e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a656a9f-8eb8-69b7-e054-00144ff8d46c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10a9e6fa-4d55-6b5c-e063-6294a90a608c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b18b43c-0de2-4acf-b0d5-f1b601d496de (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87dc077b-2c84-522b-e053-2995a90a68bc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8dff98f-185e-77ba-e053-2995a90aed2f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:288d6b40-8c87-4f16-85a7-86166b5ac77f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbf0f882-1dcc-415d-82bb-acc64f4dc2bc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e516204-8f39-43c9-9f7e-d9777586f321 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b1d3130-cf3c-d7da-e063-6294a90a6079 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48169bbc-4fb2-4bc4-9bdd-de71bf7722df (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dae6824-6913-42de-b98a-cdcb0d3b4a46 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47ef2964-3a41-4bfd-86fb-d44560b9961f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0366164b-1846-443d-9564-dbe52d8d9b65 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f39dea-f29b-d6c6-e063-6294a90a5b74 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44095c2b-2e90-45d2-ab45-d0961c41550d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50b10a3d-883c-8891-e063-6394a90a86a1 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:690baf58-1ec9-463e-99b7-d601362ea56b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e382a731-ef73-4990-bc74-ffc3a91ff3ba (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efc0d85e-fddc-4122-85b2-da2d2cb2f9d8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ef1c408-30f7-51ee-e063-6394a90ac880 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f16065c0-9949-9ac4-e053-2995a90a3b02 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d63b64dd-b420-4283-9bac-92ba43c9f429 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a30c583a-4b0a-43a6-ae76-19b1a5e916ca (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca45d478-7214-5bc7-e053-2995a90aa601 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:164cb1f7-1a41-675f-e063-6294a90ae0dd (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5424d59e-74f1-4c3c-b737-79e9776e0b60 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52ba9c4f-e7d0-4352-e063-6394a90af7e2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5826cb22-3559-171b-e063-6394a90ad594 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:546103e1-ea6e-466b-b0de-b1ff8c494512 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d9b2c1d-565e-4c43-96ef-e5cd2593d0a8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78ef4e4e-d391-4417-952b-06202d5000d8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a16d6a9-3dd1-ede8-e063-6294a90afe75 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93da6674-14dc-4c8d-9424-03e4b2b41479 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02cac021-e135-483f-bb5d-f3696eef0682 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83558f89-1adb-4d81-b19b-68721d48034b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afd4c2b9-b80c-b43a-e053-2995a90ac923 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4886adf-199d-4b19-a4ef-75f8f94cb54e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution.
Projected row 1546
- Medicine slug
- topiramate
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 155
- Source count
- 153
- Agreement rate
- 0.888889
- Recorded readings
21 hours
- Numeric value
- 21
- Unit
- hours
- Source records
- 136
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 136 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2917ba32-3355-4d64-966a-8518e6fafdbe (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bd03bb2-3b9b-4707-a9a4-5618ddc3832f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9cb3c29-098c-405f-a200-b436ac7fa1a2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f781ada8-f90d-b233-e053-6394a90a87ff (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2a4df59-fead-4a01-9021-9eda02c48010 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:149d20de-f262-4567-aa97-d4d28a1653cb (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f461f84-bfad-44fa-a2bd-5ea1566444b5 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53c3f980-f05b-c671-e063-6294a90a77d5 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5461f33d-eaef-dce3-e063-6294a90aeff8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:163e9f2d-27be-6d3f-e063-6394a90a5884 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:562f3fec-489b-4662-e063-6294a90a4ea2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46a305cb-ab73-0bca-e063-6294a90a9b85 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cefbc5f4-ef5f-4732-ab96-a69a183f0b6b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e0834ee-920b-496f-954d-f9d81c3ba2d6 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c909a53-ae66-4b28-a741-b60bb25a69cf (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68b22d22-c2d3-4e90-b302-56f7cb731427 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b6b0642-fb91-4641-9c51-d3be2021992b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf732c34-9078-496a-8093-f68594e76fcb (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61390be3-7553-4cb5-b5da-7571ed7d4b17 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffaacad8-4594-45a8-b292-02a84cd0c35b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a712d050-d5de-4685-a80a-548ab080fdb7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d6d236b-9808-4e18-b521-e7435d1fd5cc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc918c0d-2b1e-4fa0-b4d3-9dbc28718018 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30ca2fce-4e4c-439e-e063-6294a90af076 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:073d075d-d019-4834-b55d-9b9587914975 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21628112-0c47-11df-95b3-498d55d89593 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffd7be08-050e-dfcb-e053-6394a90ad286 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9221403c-467f-738e-e053-2995a90ac8fd (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca9ce6c1-5a60-467a-9ad5-acc7a9f8ca15 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:816566bf-b909-606f-e053-2a91aa0ab8c9 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:654f7c48-8c5d-4b97-88d6-397696f82b6a (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:521be3f1-3ee7-45c7-9f0c-17e08b6c8fca (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1af94c80-2b17-409a-98f6-ce00f942351d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5bc696e-040d-4d3e-b38c-9548a38fa936 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ee00e82-799d-445e-b658-a9712c49a28e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8abe45eb-cc75-4625-ae3d-5b2a038c4907 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92637f92-9d7c-c246-e053-2995a90a0347 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:872927eb-0b61-44bb-9892-3c700b6f2181 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e476c33-3590-4c6f-981d-915623cdacf0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f2aca4-b961-a746-e063-6294a90ae8ce (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be42ed09-350c-4e8a-aff4-6afb242dd599 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80481455-7ad7-4f44-8113-b8b61d8581a0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8706a35d-5c39-4daf-b83a-65f3d630e043 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e39d2549-b489-426d-b576-741537e112e7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1588c37-9da9-4ccb-b78a-64234938a115 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32b48ea0-a215-43b8-83b4-a5435a686d68 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35312f49-decf-428d-bf5f-4215b762ed3c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7539f52-06e9-4663-b401-92f5f83653cc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ce65b7f-9215-47a8-a784-f87a810bd7e4 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0cf388dc-d8f1-4478-bf5f-e64638ee5801 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b71c09c5-43dd-4d98-9ab6-0b0c99908cac (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67dcdd6e-48bc-418e-a887-805929d83ce0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d6752ce-7a56-4b04-ab15-cbd40aa5cc94 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7f2d1bc-9c65-4798-826f-6902b3ec81dc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cf7ce9e-afc2-f94e-e063-6394a90a35d0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f99b26b-79b9-4efb-aa2c-2868e1e126c8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55e71f43-1cd5-4efc-9641-fda0a09c30f0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3321dc5-0fb7-0d12-e053-2a95a90a9694 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f5b1b0b-fd8a-4c4e-a85a-519ca841a0db (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b847969-2124-4350-94b0-ef5ba707673b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57462baf-2f32-4bde-9627-2214c8af9370 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bffcd213-4f09-4a5b-8ccb-591a68be402b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:484c132f-3d3d-4218-b22f-82e9b56cc2f4 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8aaf403-0e15-4bbb-b88b-253d93439688 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c90d81a9-a87b-48b0-8cf1-172b82e30127 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bc4ec7a-9b83-4842-9057-e1a804b2596d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d9513e0-2fb8-46c9-bbd6-b03efd31c3ef (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eca774cf-2e4e-7642-e053-2a95a90a847d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57ac12ed-27f0-4f5c-96ae-a7433714b429 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:584e16c5-5ffb-4bfc-ba80-4340afd25e8e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b353e7fb-b976-96d8-e053-2995a90a110a (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49701840-5a32-4ac1-8b07-5c61decacb95 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f16b14a2-297f-4adb-8d7a-5f43785faef7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:674c2c2e-014a-43a1-91a7-7214ffc4b1d7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fb00bd8-c49e-46ef-9d6b-1b602e1d11d8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8454fdf-7b34-49c0-b130-732e39b774b2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c0a6774-e234-47a5-866e-462cfd99744c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f327383-beb3-4d15-add6-5f1c749f2b3f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5cffe7a-fdee-487a-bafb-a2d43e76c23c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6918801-f22c-4ba4-a396-da484d4334ca (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:021005ab-6a00-40d8-9aee-20c91613b4d5 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12cd9be8-c5c2-4a16-9164-87963e22a88e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e846124d-e9e6-42c7-83f1-5df170d3f70b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:610d4df7-703f-4070-9adc-3e57ca05a2f1 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:444464fb-6a95-4e10-99a7-fdbc7dbb4c48 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9c4e279-0ef9-4e96-8741-dfe7556953d9 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ddb8451-a455-87ec-e053-2995a90a5e5e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c320999e-b940-44d8-bf31-2fb78835ac2d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca4ec248-285d-4066-8f89-5ed0c538c4c9 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:490f109f-30cb-0790-e054-00144ff88e88 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4087eb3c-96e9-4d0a-b80b-663e1c86d256 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f1e4475-6326-47a3-a317-b04b74b7c109 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae63e0e2-ceb1-4cc7-88fa-92cfa4516960 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0d88f34-865c-441b-80e2-e814c9a7d670 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e914420-a65b-98ba-e063-6394a90a14c4 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4833f2e8-16b7-406f-937a-55bc978bf92c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be14624b-7eb9-4e7a-9274-1bb88270ecbe (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f66a529d-ba9d-4c8b-b58e-8fbcbcb8a11b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea0bcab1-cfe1-491c-875e-8c865449557e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a656a9f-8eb8-69b7-e054-00144ff8d46c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10a9e6fa-4d55-6b5c-e063-6294a90a608c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b18b43c-0de2-4acf-b0d5-f1b601d496de (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87dc077b-2c84-522b-e053-2995a90a68bc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8dff98f-185e-77ba-e053-2995a90aed2f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:288d6b40-8c87-4f16-85a7-86166b5ac77f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbf0f882-1dcc-415d-82bb-acc64f4dc2bc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e516204-8f39-43c9-9f7e-d9777586f321 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b1d3130-cf3c-d7da-e063-6294a90a6079 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dae6824-6913-42de-b98a-cdcb0d3b4a46 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47ef2964-3a41-4bfd-86fb-d44560b9961f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0366164b-1846-443d-9564-dbe52d8d9b65 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f39dea-f29b-d6c6-e063-6294a90a5b74 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44095c2b-2e90-45d2-ab45-d0961c41550d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50b10a3d-883c-8891-e063-6394a90a86a1 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:690baf58-1ec9-463e-99b7-d601362ea56b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:035bf713-1642-4215-83ec-0ed07c29f92c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e382a731-ef73-4990-bc74-ffc3a91ff3ba (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efc0d85e-fddc-4122-85b2-da2d2cb2f9d8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ef1c408-30f7-51ee-e063-6394a90ac880 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f16065c0-9949-9ac4-e053-2995a90a3b02 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d63b64dd-b420-4283-9bac-92ba43c9f429 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a30c583a-4b0a-43a6-ae76-19b1a5e916ca (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca45d478-7214-5bc7-e053-2995a90aa601 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:164cb1f7-1a41-675f-e063-6294a90ae0dd (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5424d59e-74f1-4c3c-b737-79e9776e0b60 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52ba9c4f-e7d0-4352-e063-6394a90af7e2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5826cb22-3559-171b-e063-6394a90ad594 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:546103e1-ea6e-466b-b0de-b1ff8c494512 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d9b2c1d-565e-4c43-96ef-e5cd2593d0a8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78ef4e4e-d391-4417-952b-06202d5000d8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a16d6a9-3dd1-ede8-e063-6294a90afe75 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93da6674-14dc-4c8d-9424-03e4b2b41479 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02cac021-e135-483f-bb5d-f3696eef0682 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83558f89-1adb-4d81-b19b-68721d48034b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afd4c2b9-b80c-b43a-e053-2995a90ac923 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4886adf-199d-4b19-a4ef-75f8f94cb54e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life is 21 hours after single or multiple doses.
31 hours
- Numeric value
- 31
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dc7957e-a3e5-46bb-aa66-f3250f872f5e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean elimination half-life of topiramate was approximately 31 hours following repeat administration of TROKENDI XR.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25b377f7-ea89-fb56-e063-6394a90a239d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean elimination half-life of topiramate was approximately 31 hours following repeat administration of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbc52b16-b93d-4d83-942b-485c502db1fa (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean elimination half-life of topiramate was approximately 31 hours following repeat administration of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f20155f-05b9-40ec-af34-3b58aa8d60d4 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean elimination half-life of topiramate was approximately 31 hours following repeat administration of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ac09563-5967-498c-93ae-675a7f4efc48 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean elimination half-life of topiramate was approximately 31 hours following repeat administration of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11e0924b-fbee-4ec4-b1e4-22d7683b21ee (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean elimination half-life of topiramate was approximately 31 hours following repeat administration of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f72774dd-c7eb-41f9-9837-02baf77cc523 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean elimination half-life of topiramate was approximately 31 hours following repeat administration of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b94629e3-ae2e-473e-b2f5-06e32ee19aa9 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean elimination half-life of topiramate was approximately 31 hours following repeat administration of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f07d81bc-5090-fbc5-2945-557cf002849c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean elimination half-life of topiramate was approximately 31 hours following repeat administration of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e310afcd-1260-434e-a994-34549c789d99 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean elimination half-life of topiramate was approximately 31 hours following repeat administration of topiramate extended-release capsules.
56 hours
- Numeric value
- 56
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:691d276c-9cc1-4d39-828f-0f44d7ef6328 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean effective half-life of topiramate extended-release is approximately 56 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:813f5fe2-df82-479c-8014-d503ff5df52b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean effective half-life of topiramate extended-release capsules is approximately 56 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5f8da43-6daf-413c-9dcd-363617973738 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean effective half-life of topiramate extended-release capsules are approximately 56 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5ca2fce-bd2d-40db-b963-e3ec27c8bf23 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean effective half-life of topiramate extended-release capsules is approximately 56 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9d7c5ef-daf9-4f97-8673-7f4a2007f408 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean effective half-life of topiramate extended-release is approximately 56 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54bfabce-1f8a-40ee-8b55-efce8fe6fbf1 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean effective half-life of topiramate extended-release capsules are approximately 56 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46f54677-3a22-4c38-9b92-923020164e15 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The mean effective half-life of QUDEXY XR is approximately 56 hours.
Projected row 1547
- Medicine slug
- topiramate
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 155
- Source count
- 155
- Agreement rate
- 1
- Recorded readings
23%
- Numeric value
- 23
- Unit
- %
- Source records
- 155
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 155 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2917ba32-3355-4d64-966a-8518e6fafdbe (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bd03bb2-3b9b-4707-a9a4-5618ddc3832f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9cb3c29-098c-405f-a200-b436ac7fa1a2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f781ada8-f90d-b233-e053-6394a90a87ff (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2a4df59-fead-4a01-9021-9eda02c48010 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:149d20de-f262-4567-aa97-d4d28a1653cb (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f461f84-bfad-44fa-a2bd-5ea1566444b5 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53c3f980-f05b-c671-e063-6294a90a77d5 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5461f33d-eaef-dce3-e063-6294a90aeff8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:163e9f2d-27be-6d3f-e063-6394a90a5884 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 µg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:562f3fec-489b-4662-e063-6294a90a4ea2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46a305cb-ab73-0bca-e063-6294a90a9b85 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cefbc5f4-ef5f-4732-ab96-a69a183f0b6b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e0834ee-920b-496f-954d-f9d81c3ba2d6 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c909a53-ae66-4b28-a741-b60bb25a69cf (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dc7957e-a3e5-46bb-aa66-f3250f872f5e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68b22d22-c2d3-4e90-b302-56f7cb731427 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb966bcb-3af7-4dbe-b540-58d473b891e5 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b6b0642-fb91-4641-9c51-d3be2021992b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf732c34-9078-496a-8093-f68594e76fcb (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61390be3-7553-4cb5-b5da-7571ed7d4b17 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffaacad8-4594-45a8-b292-02a84cd0c35b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a712d050-d5de-4685-a80a-548ab080fdb7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d6d236b-9808-4e18-b521-e7435d1fd5cc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc918c0d-2b1e-4fa0-b4d3-9dbc28718018 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30ca2fce-4e4c-439e-e063-6294a90af076 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:073d075d-d019-4834-b55d-9b9587914975 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25b377f7-ea89-fb56-e063-6394a90a239d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21628112-0c47-11df-95b3-498d55d89593 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 µg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffd7be08-050e-dfcb-e053-6394a90ad286 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9221403c-467f-738e-e053-2995a90ac8fd (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca9ce6c1-5a60-467a-9ad5-acc7a9f8ca15 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:691d276c-9cc1-4d39-828f-0f44d7ef6328 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:816566bf-b909-606f-e053-2a91aa0ab8c9 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:654f7c48-8c5d-4b97-88d6-397696f82b6a (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:521be3f1-3ee7-45c7-9f0c-17e08b6c8fca (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1af94c80-2b17-409a-98f6-ce00f942351d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5bc696e-040d-4d3e-b38c-9548a38fa936 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ee00e82-799d-445e-b658-a9712c49a28e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbc52b16-b93d-4d83-942b-485c502db1fa (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8abe45eb-cc75-4625-ae3d-5b2a038c4907 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92637f92-9d7c-c246-e053-2995a90a0347 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:872927eb-0b61-44bb-9892-3c700b6f2181 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e476c33-3590-4c6f-981d-915623cdacf0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f2aca4-b961-a746-e063-6294a90ae8ce (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:813f5fe2-df82-479c-8014-d503ff5df52b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be42ed09-350c-4e8a-aff4-6afb242dd599 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80481455-7ad7-4f44-8113-b8b61d8581a0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8706a35d-5c39-4daf-b83a-65f3d630e043 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e39d2549-b489-426d-b576-741537e112e7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1588c37-9da9-4ccb-b78a-64234938a115 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32b48ea0-a215-43b8-83b4-a5435a686d68 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35312f49-decf-428d-bf5f-4215b762ed3c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7539f52-06e9-4663-b401-92f5f83653cc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ce65b7f-9215-47a8-a784-f87a810bd7e4 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0cf388dc-d8f1-4478-bf5f-e64638ee5801 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b71c09c5-43dd-4d98-9ab6-0b0c99908cac (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67dcdd6e-48bc-418e-a887-805929d83ce0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d6752ce-7a56-4b04-ab15-cbd40aa5cc94 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7f2d1bc-9c65-4798-826f-6902b3ec81dc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cf7ce9e-afc2-f94e-e063-6394a90a35d0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f99b26b-79b9-4efb-aa2c-2868e1e126c8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55e71f43-1cd5-4efc-9641-fda0a09c30f0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3321dc5-0fb7-0d12-e053-2a95a90a9694 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f5b1b0b-fd8a-4c4e-a85a-519ca841a0db (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b847969-2124-4350-94b0-ef5ba707673b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57462baf-2f32-4bde-9627-2214c8af9370 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bffcd213-4f09-4a5b-8ccb-591a68be402b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:484c132f-3d3d-4218-b22f-82e9b56cc2f4 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8aaf403-0e15-4bbb-b88b-253d93439688 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f20155f-05b9-40ec-af34-3b58aa8d60d4 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c90d81a9-a87b-48b0-8cf1-172b82e30127 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bc4ec7a-9b83-4842-9057-e1a804b2596d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d9513e0-2fb8-46c9-bbd6-b03efd31c3ef (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eca774cf-2e4e-7642-e053-2a95a90a847d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57ac12ed-27f0-4f5c-96ae-a7433714b429 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:584e16c5-5ffb-4bfc-ba80-4340afd25e8e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b353e7fb-b976-96d8-e053-2995a90a110a (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ac09563-5967-498c-93ae-675a7f4efc48 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49701840-5a32-4ac1-8b07-5c61decacb95 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f16b14a2-297f-4adb-8d7a-5f43785faef7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:674c2c2e-014a-43a1-91a7-7214ffc4b1d7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fb00bd8-c49e-46ef-9d6b-1b602e1d11d8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8454fdf-7b34-49c0-b130-732e39b774b2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c0a6774-e234-47a5-866e-462cfd99744c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f327383-beb3-4d15-add6-5f1c749f2b3f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5cffe7a-fdee-487a-bafb-a2d43e76c23c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6918801-f22c-4ba4-a396-da484d4334ca (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5f8da43-6daf-413c-9dcd-363617973738 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:021005ab-6a00-40d8-9aee-20c91613b4d5 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12cd9be8-c5c2-4a16-9164-87963e22a88e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e846124d-e9e6-42c7-83f1-5df170d3f70b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:610d4df7-703f-4070-9adc-3e57ca05a2f1 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5ca2fce-bd2d-40db-b963-e3ec27c8bf23 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 times to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:444464fb-6a95-4e10-99a7-fdbc7dbb4c48 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9c4e279-0ef9-4e96-8741-dfe7556953d9 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg /mL (a concentration 5 to10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ddb8451-a455-87ec-e053-2995a90a5e5e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11e0924b-fbee-4ec4-b1e4-22d7683b21ee (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c320999e-b940-44d8-bf31-2fb78835ac2d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca4ec248-285d-4066-8f89-5ed0c538c4c9 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:490f109f-30cb-0790-e054-00144ff88e88 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4087eb3c-96e9-4d0a-b80b-663e1c86d256 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f1e4475-6326-47a3-a317-b04b74b7c109 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae63e0e2-ceb1-4cc7-88fa-92cfa4516960 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0d88f34-865c-441b-80e2-e814c9a7d670 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 µg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e914420-a65b-98ba-e063-6394a90a14c4 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4833f2e8-16b7-406f-937a-55bc978bf92c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be14624b-7eb9-4e7a-9274-1bb88270ecbe (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f66a529d-ba9d-4c8b-b58e-8fbcbcb8a11b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea0bcab1-cfe1-491c-875e-8c865449557e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a656a9f-8eb8-69b7-e054-00144ff8d46c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10a9e6fa-4d55-6b5c-e063-6294a90a608c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b18b43c-0de2-4acf-b0d5-f1b601d496de (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87dc077b-2c84-522b-e053-2995a90a68bc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8dff98f-185e-77ba-e053-2995a90aed2f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:288d6b40-8c87-4f16-85a7-86166b5ac77f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbf0f882-1dcc-415d-82bb-acc64f4dc2bc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e516204-8f39-43c9-9f7e-d9777586f321 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b1d3130-cf3c-d7da-e063-6294a90a6079 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48169bbc-4fb2-4bc4-9bdd-de71bf7722df (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9d7c5ef-daf9-4f97-8673-7f4a2007f408 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dae6824-6913-42de-b98a-cdcb0d3b4a46 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47ef2964-3a41-4bfd-86fb-d44560b9961f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0366164b-1846-443d-9564-dbe52d8d9b65 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f39dea-f29b-d6c6-e063-6294a90a5b74 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44095c2b-2e90-45d2-ab45-d0961c41550d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50b10a3d-883c-8891-e063-6394a90a86a1 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:690baf58-1ec9-463e-99b7-d601362ea56b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:035bf713-1642-4215-83ec-0ed07c29f92c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e382a731-ef73-4990-bc74-ffc3a91ff3ba (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efc0d85e-fddc-4122-85b2-da2d2cb2f9d8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ef1c408-30f7-51ee-e063-6394a90ac880 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f16065c0-9949-9ac4-e053-2995a90a3b02 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d63b64dd-b420-4283-9bac-92ba43c9f429 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a30c583a-4b0a-43a6-ae76-19b1a5e916ca (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca45d478-7214-5bc7-e053-2995a90aa601 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:164cb1f7-1a41-675f-e063-6294a90ae0dd (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5424d59e-74f1-4c3c-b737-79e9776e0b60 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f72774dd-c7eb-41f9-9837-02baf77cc523 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 times to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54bfabce-1f8a-40ee-8b55-efce8fe6fbf1 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52ba9c4f-e7d0-4352-e063-6394a90af7e2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b94629e3-ae2e-473e-b2f5-06e32ee19aa9 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5826cb22-3559-171b-e063-6394a90ad594 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:546103e1-ea6e-466b-b0de-b1ff8c494512 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d9b2c1d-565e-4c43-96ef-e5cd2593d0a8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78ef4e4e-d391-4417-952b-06202d5000d8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a16d6a9-3dd1-ede8-e063-6294a90afe75 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93da6674-14dc-4c8d-9424-03e4b2b41479 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02cac021-e135-483f-bb5d-f3696eef0682 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 μg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83558f89-1adb-4d81-b19b-68721d48034b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afd4c2b9-b80c-b43a-e053-2995a90ac923 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f07d81bc-5090-fbc5-2945-557cf002849c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e310afcd-1260-434e-a994-34549c789d99 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46f54677-3a22-4c38-9b92-923020164e15 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of immediate-release topiramate from 23% to 13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4886adf-199d-4b19-a4ef-75f8f94cb54e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Sodium valproate, at 500 mcg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%.
Projected row 1548
- Medicine slug
- topiramate
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 155
- Source count
- 151
- Agreement rate
- 0.887417
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 134
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 134 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2917ba32-3355-4d64-966a-8518e6fafdbe (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bd03bb2-3b9b-4707-a9a4-5618ddc3832f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9cb3c29-098c-405f-a200-b436ac7fa1a2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f781ada8-f90d-b233-e053-6394a90a87ff (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The clinical significance of these various changes in vital signs has not been clearly established. 12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:149d20de-f262-4567-aa97-d4d28a1653cb (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f461f84-bfad-44fa-a2bd-5ea1566444b5 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53c3f980-f05b-c671-e063-6294a90a77d5 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5461f33d-eaef-dce3-e063-6294a90aeff8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:163e9f2d-27be-6d3f-e063-6394a90a5884 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:562f3fec-489b-4662-e063-6294a90a4ea2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46a305cb-ab73-0bca-e063-6294a90a9b85 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cefbc5f4-ef5f-4732-ab96-a69a183f0b6b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e0834ee-920b-496f-954d-f9d81c3ba2d6 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c909a53-ae66-4b28-a741-b60bb25a69cf (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68b22d22-c2d3-4e90-b302-56f7cb731427 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb966bcb-3af7-4dbe-b540-58d473b891e5 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b6b0642-fb91-4641-9c51-d3be2021992b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf732c34-9078-496a-8093-f68594e76fcb (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61390be3-7553-4cb5-b5da-7571ed7d4b17 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffaacad8-4594-45a8-b292-02a84cd0c35b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a712d050-d5de-4685-a80a-548ab080fdb7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d6d236b-9808-4e18-b521-e7435d1fd5cc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc918c0d-2b1e-4fa0-b4d3-9dbc28718018 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30ca2fce-4e4c-439e-e063-6294a90af076 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:073d075d-d019-4834-b55d-9b9587914975 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21628112-0c47-11df-95b3-498d55d89593 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffd7be08-050e-dfcb-e053-6394a90ad286 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9221403c-467f-738e-e053-2995a90ac8fd (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca9ce6c1-5a60-467a-9ad5-acc7a9f8ca15 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:816566bf-b909-606f-e053-2a91aa0ab8c9 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:654f7c48-8c5d-4b97-88d6-397696f82b6a (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:521be3f1-3ee7-45c7-9f0c-17e08b6c8fca (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1af94c80-2b17-409a-98f6-ce00f942351d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5bc696e-040d-4d3e-b38c-9548a38fa936 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ee00e82-799d-445e-b658-a9712c49a28e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8abe45eb-cc75-4625-ae3d-5b2a038c4907 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92637f92-9d7c-c246-e053-2995a90a0347 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:872927eb-0b61-44bb-9892-3c700b6f2181 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e476c33-3590-4c6f-981d-915623cdacf0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f2aca4-b961-a746-e063-6294a90ae8ce (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be42ed09-350c-4e8a-aff4-6afb242dd599 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80481455-7ad7-4f44-8113-b8b61d8581a0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8706a35d-5c39-4daf-b83a-65f3d630e043 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e39d2549-b489-426d-b576-741537e112e7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1588c37-9da9-4ccb-b78a-64234938a115 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32b48ea0-a215-43b8-83b4-a5435a686d68 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35312f49-decf-428d-bf5f-4215b762ed3c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7539f52-06e9-4663-b401-92f5f83653cc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ce65b7f-9215-47a8-a784-f87a810bd7e4 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0cf388dc-d8f1-4478-bf5f-e64638ee5801 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b71c09c5-43dd-4d98-9ab6-0b0c99908cac (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67dcdd6e-48bc-418e-a887-805929d83ce0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d6752ce-7a56-4b04-ab15-cbd40aa5cc94 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7f2d1bc-9c65-4798-826f-6902b3ec81dc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cf7ce9e-afc2-f94e-e063-6394a90a35d0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f99b26b-79b9-4efb-aa2c-2868e1e126c8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55e71f43-1cd5-4efc-9641-fda0a09c30f0 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3321dc5-0fb7-0d12-e053-2a95a90a9694 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f5b1b0b-fd8a-4c4e-a85a-519ca841a0db (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b847969-2124-4350-94b0-ef5ba707673b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57462baf-2f32-4bde-9627-2214c8af9370 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bffcd213-4f09-4a5b-8ccb-591a68be402b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:484c132f-3d3d-4218-b22f-82e9b56cc2f4 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8aaf403-0e15-4bbb-b88b-253d93439688 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c90d81a9-a87b-48b0-8cf1-172b82e30127 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d9513e0-2fb8-46c9-bbd6-b03efd31c3ef (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eca774cf-2e4e-7642-e053-2a95a90a847d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The clinical significance of these various changes in vital signs has not been clearly established. 12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57ac12ed-27f0-4f5c-96ae-a7433714b429 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:584e16c5-5ffb-4bfc-ba80-4340afd25e8e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b353e7fb-b976-96d8-e053-2995a90a110a (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49701840-5a32-4ac1-8b07-5c61decacb95 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f16b14a2-297f-4adb-8d7a-5f43785faef7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:674c2c2e-014a-43a1-91a7-7214ffc4b1d7 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fb00bd8-c49e-46ef-9d6b-1b602e1d11d8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8454fdf-7b34-49c0-b130-732e39b774b2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c0a6774-e234-47a5-866e-462cfd99744c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f327383-beb3-4d15-add6-5f1c749f2b3f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5cffe7a-fdee-487a-bafb-a2d43e76c23c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6918801-f22c-4ba4-a396-da484d4334ca (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:021005ab-6a00-40d8-9aee-20c91613b4d5 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12cd9be8-c5c2-4a16-9164-87963e22a88e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e846124d-e9e6-42c7-83f1-5df170d3f70b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:610d4df7-703f-4070-9adc-3e57ca05a2f1 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:444464fb-6a95-4e10-99a7-fdbc7dbb4c48 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9c4e279-0ef9-4e96-8741-dfe7556953d9 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ddb8451-a455-87ec-e053-2995a90a5e5e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c320999e-b940-44d8-bf31-2fb78835ac2d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca4ec248-285d-4066-8f89-5ed0c538c4c9 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:490f109f-30cb-0790-e054-00144ff88e88 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4087eb3c-96e9-4d0a-b80b-663e1c86d256 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f1e4475-6326-47a3-a317-b04b74b7c109 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae63e0e2-ceb1-4cc7-88fa-92cfa4516960 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0d88f34-865c-441b-80e2-e814c9a7d670 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4833f2e8-16b7-406f-937a-55bc978bf92c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be14624b-7eb9-4e7a-9274-1bb88270ecbe (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f66a529d-ba9d-4c8b-b58e-8fbcbcb8a11b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea0bcab1-cfe1-491c-875e-8c865449557e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a656a9f-8eb8-69b7-e054-00144ff8d46c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10a9e6fa-4d55-6b5c-e063-6294a90a608c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b18b43c-0de2-4acf-b0d5-f1b601d496de (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87dc077b-2c84-522b-e053-2995a90a68bc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8dff98f-185e-77ba-e053-2995a90aed2f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The clinical significance of these various changes in vital signs has not been clearly established. 12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:288d6b40-8c87-4f16-85a7-86166b5ac77f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbf0f882-1dcc-415d-82bb-acc64f4dc2bc (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e516204-8f39-43c9-9f7e-d9777586f321 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b1d3130-cf3c-d7da-e063-6294a90a6079 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48169bbc-4fb2-4bc4-9bdd-de71bf7722df (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dae6824-6913-42de-b98a-cdcb0d3b4a46 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47ef2964-3a41-4bfd-86fb-d44560b9961f (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0366164b-1846-443d-9564-dbe52d8d9b65 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f39dea-f29b-d6c6-e063-6294a90a5b74 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44095c2b-2e90-45d2-ab45-d0961c41550d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50b10a3d-883c-8891-e063-6394a90a86a1 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:690baf58-1ec9-463e-99b7-d601362ea56b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e382a731-ef73-4990-bc74-ffc3a91ff3ba (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efc0d85e-fddc-4122-85b2-da2d2cb2f9d8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ef1c408-30f7-51ee-e063-6394a90ac880 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f16065c0-9949-9ac4-e053-2995a90a3b02 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The clinical significance of these various changes in vital signs has not been clearly established. 12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d63b64dd-b420-4283-9bac-92ba43c9f429 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a30c583a-4b0a-43a6-ae76-19b1a5e916ca (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca45d478-7214-5bc7-e053-2995a90aa601 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:164cb1f7-1a41-675f-e063-6294a90ae0dd (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The clinical significance of these various changes in vital signs has not been clearly established. 12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5424d59e-74f1-4c3c-b737-79e9776e0b60 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52ba9c4f-e7d0-4352-e063-6394a90af7e2 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5826cb22-3559-171b-e063-6394a90ad594 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:546103e1-ea6e-466b-b0de-b1ff8c494512 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d9b2c1d-565e-4c43-96ef-e5cd2593d0a8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78ef4e4e-d391-4417-952b-06202d5000d8 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a16d6a9-3dd1-ede8-e063-6294a90afe75 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93da6674-14dc-4c8d-9424-03e4b2b41479 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02cac021-e135-483f-bb5d-f3696eef0682 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83558f89-1adb-4d81-b19b-68721d48034b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afd4c2b9-b80c-b43a-e053-2995a90ac923 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4886adf-199d-4b19-a4ef-75f8f94cb54e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose.
24 hours
- Numeric value
- 24
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dc7957e-a3e5-46bb-aa66-f3250f872f5e (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The peak plasma concentrations (C max ) of topiramate occurred at approximately 24 hours following a single 200 mg oral dose of TROKENDI XR.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25b377f7-ea89-fb56-e063-6394a90a239d (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The peak plasma concentrations (C max ) of topiramate occurred at approximately 24 hours following a single 200 mg oral dose of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbc52b16-b93d-4d83-942b-485c502db1fa (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The peak plasma concentrations (C max ) of topiramate occurred at approximately 24 hours following a single 200 mg oral dose of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f20155f-05b9-40ec-af34-3b58aa8d60d4 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The peak plasma concentrations (C max ) of topiramate occurred at approximately 24 hours following a single 200 mg oral dose of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ac09563-5967-498c-93ae-675a7f4efc48 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The peak plasma concentrations (C max ) of topiramate occurred at approximately 24 hours following a single 200 mg oral dose of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11e0924b-fbee-4ec4-b1e4-22d7683b21ee (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The peak plasma concentrations (C max ) of topiramate occurred at approximately 24 hours following a single 200 mg oral dose of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f72774dd-c7eb-41f9-9837-02baf77cc523 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The peak plasma concentrations (C max ) of topiramate occurred at approximately 24 hours following a single 200 mg oral dose of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b94629e3-ae2e-473e-b2f5-06e32ee19aa9 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The peak plasma concentrations (C max ) of topiramate occurred at approximately 24 hours following a single 200 mg oral dose of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f07d81bc-5090-fbc5-2945-557cf002849c (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The peak plasma concentrations (C max ) of topiramate occurred at approximately 24 hours following a single 200 mg oral dose of topiramate extended-release capsules.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e310afcd-1260-434e-a994-34549c789d99 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
The peak plasma concentrations (C max ) of topiramate occurred at approximately 24 hours following a single 200 mg oral dose of topiramate extended-release capsules.
20 hours
- Numeric value
- 20
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:691d276c-9cc1-4d39-828f-0f44d7ef6328 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Following a single 200 mg oral dose of topiramate extended-release, peak plasma concentrations (T max ) occurred approximately 20 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:813f5fe2-df82-479c-8014-d503ff5df52b (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Following a single 200 mg oral dose of topiramate extended-release capsules, peak plasma concentrations (T max ) occurred approximately 20 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5f8da43-6daf-413c-9dcd-363617973738 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Following a single 200 mg oral dose of topiramate extended-release, peak plasma concentrations (T max ) occurred approximately 20 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5ca2fce-bd2d-40db-b963-e3ec27c8bf23 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Following a single 200 mg oral dose of topiramate extended-release capsules, peak plasma concentrations (T max ) occurred approximately 20 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9d7c5ef-daf9-4f97-8673-7f4a2007f408 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Following a single 200 mg oral dose of topiramate extended-release, peak plasma concentrations (T max ) occurred approximately 20 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54bfabce-1f8a-40ee-8b55-efce8fe6fbf1 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Following a single 200 mg oral dose of topiramate extended-release, peak plasma concentrations (T max ) occurred approximately 20 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46f54677-3a22-4c38-9b92-923020164e15 (opens source in a new tab)
Topiramate label
Version not recorded · Effective date not recorded
Following a single 200 mg oral dose of QUDEXY XR, peak plasma concentrations (T max ) occurred approximately 20 hours after dosing.
Projected row 1549
- Medicine slug
- topotecan
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 7
- Source count
- 7
- Agreement rate
- 0.857143
- Recorded readings
2 to 3 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7636bc1e-77b6-46ad-9df0-c8bb1c5e503f (opens source in a new tab)
Topotecan label
Version not recorded · Effective date not recorded
Topotecan exhibits multiexponential pharmacokinetics with a terminal half-life of 2 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d4e1cce-c57e-4a8b-be96-f95a2778e221 (opens source in a new tab)
Topotecan label
Version not recorded · Effective date not recorded
Elimination The terminal half-life of topotecan is 2 to 3 hours following intravenous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:729b2b22-1344-44f3-b614-14f6ec3c263e (opens source in a new tab)
Topotecan label
Version not recorded · Effective date not recorded
Elimination The terminal half-life of topotecan is 2 to 3 hours following intravenous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeee060c-a9ec-423e-a374-8484009f8524 (opens source in a new tab)
Topotecan label
Version not recorded · Effective date not recorded
Elimination The terminal half-life of topotecan is 2 to 3 hours following intravenous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:996430c0-ee26-4ed9-82b8-a8b645becba6 (opens source in a new tab)
Topotecan label
Version not recorded · Effective date not recorded
Elimination The terminal half-life of topotecan is 2 to 3 hours following intravenous administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6019088-cd94-43b4-b5ce-ba20b6b8021e (opens source in a new tab)
Topotecan label
Version not recorded · Effective date not recorded
Elimination The terminal half-life of topotecan is 2 to 3 hours following intravenous administration.
3 to 6 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b23b46f5-c276-47f5-8bbd-940680b3f579 (opens source in a new tab)
Topotecan label
Version not recorded · Effective date not recorded
Elimination The mean terminal half-life (t½) of topotecan is 3 to 6 hours following oral administration.
Projected row 1550
- Medicine slug
- topotecan
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
35%
- Numeric value
- 35
- Unit
- %
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b23b46f5-c276-47f5-8bbd-940680b3f579 (opens source in a new tab)
Topotecan label
Version not recorded · Effective date not recorded
Distribution Protein binding of topotecan is approximately 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d4e1cce-c57e-4a8b-be96-f95a2778e221 (opens source in a new tab)
Topotecan label
Version not recorded · Effective date not recorded
Distribution Protein binding of topotecan is approximately 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:729b2b22-1344-44f3-b614-14f6ec3c263e (opens source in a new tab)
Topotecan label
Version not recorded · Effective date not recorded
Distribution Protein binding of topotecan is approximately 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeee060c-a9ec-423e-a374-8484009f8524 (opens source in a new tab)
Topotecan label
Version not recorded · Effective date not recorded
Distribution Protein binding of topotecan is approximately 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:996430c0-ee26-4ed9-82b8-a8b645becba6 (opens source in a new tab)
Topotecan label
Version not recorded · Effective date not recorded
Distribution Protein binding of topotecan is approximately 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6019088-cd94-43b4-b5ce-ba20b6b8021e (opens source in a new tab)
Topotecan label
Version not recorded · Effective date not recorded
Distribution Protein binding of topotecan is approximately 35%.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1540Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.